Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 415 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
415 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine cancer are eligible if their tumors express the NEO-201 antigen in at least 10% of cells. Treatment combines NEO-201, an investigational antibody targeting tumor-associated core 1 and extended core 1 O-glycans, with the PD-1 inhibitor pembrolizumab.
ClinicalTrials.gov ID: NCT03476681
TrialFetch AI summary: Adults with advanced, measurable EGFR-mutant or wild-type NSCLC, oral-cavity head and neck squamous-cell carcinoma, or colorectal cancer may be eligible, depending on the cohort. Treatment is AZD9592, an investigational EGFR/c-MET-targeting antibody–drug conjugate that delivers a topoisomerase-I inhibitor, alone or with osimertinib for EGFR-mutant NSCLC or 5-fluorouracil, leucovorin, and bevacizumab for colorectal cancer.
ClinicalTrials.gov ID: NCT05647122
TrialFetch AI summary: Adults with previously treated unresectable stage IIIC/IIID or IV melanoma or stage III/IV NSCLC who have a resectable tumor lesion and separate measurable disease receive autologous tumor-infiltrating lymphocytes (IOV-4001) made from their tumor. The cells are gene-edited to inactivate PD-1, aiming to reduce inhibitory checkpoint signaling.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: Eligible patients have measurable locally advanced or metastatic solid tumors, ECOG performance status ≤2, and at least one prior systemic therapy; expansion cohorts focus on previously treated head and neck squamous cell carcinoma, non-small-cell lung cancer, clear-cell renal cell carcinoma, and PD-1/PD-L1-refractory MSI-high tumors. Treatment is oral ABBV-CLS-484, an investigational PTPN2/PTPN1 inhibitor, alone or with a PD-1 inhibitor or VEGFR tyrosine kinase inhibitor.
ClinicalTrials.gov ID: NCT04777994
TrialFetch AI summary: Adults with measurable metastatic or unresectable cancer, ECOG 0–1, and no suitable standard treatment option may receive oral NX-1607, a CBL-B inhibitor intended to enhance T-cell antitumor activity. Selected tumor cohorts receive NX-1607 with paclitaxel.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic antigen-rich solid tumors and no more than three prior lines of therapy for advanced disease receive intravenous STAR0602 (invikafusp alfa) monotherapy. This investigational antibody–cytokine fusion targets T-cell receptor Vβ6/Vβ10 subsets and stimulates the IL-2 receptor to expand potentially tumor-reactive T cells.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.
ClinicalTrials.gov ID: NCT03556228
TrialFetch AI summary: Adults with platinum-refractory extensive-stage lung cancer or stage IV non-small cell lung cancer who have received a PD-1 or PD-L1 inhibitor receive lymphodepleting chemotherapy followed by autologous GD2-targeted CAR T cells. The cells express IL-15 to support persistence and contain an inducible caspase-9 safety switch.
ClinicalTrials.gov ID: NCT05620342
TrialFetch AI summary: For patients with metastatic NSCLC harboring an activating EGFR exon 19 or 21 mutation, including those who are EGFR-TKI naive or have progressed after an EGFR TKI. Patients receive daily oral osimertinib plus investigational MRX-2843, a MERTK/FLT3 tyrosine kinase inhibitor.
ClinicalTrials.gov ID: NCT04762199
TrialFetch AI summary: Adults with measurable recurrent or metastatic NSCLC, ECOG 0–1, and no curative option are eligible after prior chemotherapy and PD-1/PD-L1 therapy; those with actionable mutations must also have received available approved treatments. Patients receive oral PBF-1129, an investigational adenosine A2B receptor antagonist intended to reduce tumor-associated immune suppression, plus intravenous nivolumab, an anti-PD-1 antibody.
ClinicalTrials.gov ID: NCT05234307